Video

Dr. Aggarwal on Emerging Treatment Approaches in ALK+ NSCLC

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, a medical oncologist at Abramson Cancer Center and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer (NSCLC).

There are several emerging approaches in this space, ​including the idea of targeting resistance mutations, says Aggarwal. However, this has not been feasible thus far.

Lorlatinib (Lorbrena) is a promising agent as it targets a number of mutations that emerge after a patient has been treated with a second-generation TKI, says Aggarwal. However, treatment following lorlatinib is not as well defined.

The true value of chemotherapy in this situation, along with the utility of lorlatinib in the first-line setting​ needs to be further assessed, ​Aggarwal says.

​These topics will be further discussed at the 21st Annual International Lung Cancer Congress®, Aggarwal concludes.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.